Open an account

Artivion

AORT · NYSE

$23.09+$0.81 (+3.64%)TodayMarket closed ·
Prev close $22.28

About AORT

Artivion, Inc. engages in the manufacture, processing, and distribution of medical devices and implantable human tissues used in cardiac and vascular surgical procedures for patients with aortic disease. The company is headquartered in Kennesaw, Georgia and currently employs 1,800 full-time employees. The firm operates through two segments, which include Medical Devices and Preservation Services. The medical devices and preservation services are primarily used by cardiac and vascular surgeons to treat patients with aortic disease, including heart valve disease, aortic aneurysms, and dissections, and, to a lesser extent, other conditions in cardiac and vascular surgery. The company has four product families: aortic stent grafts, On-X mechanical heart valves and related surgical products, surgical sealants, and implantable cardiac and vascular human tissues. Its aortic stent grafts include aortic arch stent grafts, abdominal stent grafts, and synthetic vascular grafts. Its surgical sealants include BioGlue Surgical Adhesive products.

Employees
1,800
Headquarters
Kennesaw, Georgia
Listed
Feb 12, 1993
Sector
Health Care
Industry
Health Care Equipment & Supplies
Website
artivion.com

AORT key statistics

Market cap
1.13B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
508.74K
Volume
631.12K
Open price
$23.11
High today
$23.69
Low today
$22.81
52 Week high
$48.25
52 Week low
$19.16

Artivion (AORT) at a glance

As of Oct 20, 2026, Artivion (AORT) shares are priced at $23.09, giving the company a market cap of 1.13B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $22.81 and $23.69. The current price is 1.2% above the day's low and 2.5% below its high.

Volume so far is 631.12K shares, above the average of 508.74K shares a day.

Over the past year Artivion has ranged from $19.16 to $48.25, and now sits 14% of the way up that range.

Artivion met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported -$0.28 per share against an estimate of $0.0102.

The average analyst price target is $42.99, 86.2% above the current price, from 5 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 5 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 10 analystsAvg $42.99
Low
$38.38
Now
$23.09
High
$50.40

AORT earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 568.8% on average.

  1. Q3 FY24: reported -$0.05 per share against an estimate of -$0.0646
  2. Q4 FY24: reported -$0.39 per share against an estimate of -$0.0612
  3. Q1 FY25: reported -$0.01 per share against an estimate of -$0.1207
  4. Q2 FY25: reported $0.08 per share against an estimate of -$0.0044
  5. Q3 FY25: reported $0.06 per share against an estimate of $0.0175
  6. Q4 FY25: reported $0.05 per share against an estimate of $0.0833
  7. Q1 FY26: reported $0.03 per share against an estimate of $0.0501
  8. Q2 FY26: reported -$0.28 per share against an estimate of $0.0102

AORT news

  • Press releasePRNewswire

    Artivion Reports Second Quarter 2026 Financial Results

  • Press releasePRNewswire

    Artivion to Participate in Upcoming Investor Conferences

  • Press releasePRNewswire

    Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2026 Financial Results

  • Vandana Singh

    Artivion Seeks To Tap $150 Million US Market Opportunity With FDA Approval

  • Press releasePRNewswire

    Artivion Announces U.S. FDA Approval of the AMDS Hybrid Prosthesis

  • Press releasePRNewswire

    Artivion to Participate in the 2026 Truist Securities MedTech Conference

  • Press releaseBusiness Wire

    Endospan Announces Closing of Acquisition by Artivion, Inc., Following FDA PMA Approval of the NEXUS® Aortic Arch System

  • Press releasePRNewswire

    Artivion Completes Acquisition of Endospan Ltd.

Similar companies

Companies in the same industry as Artivion

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.